The reactivity of cysteines of 3CLpro affects the oligomerization state of the Sars-CoV-2 protease

被引：0
|
作者：
Cipollone, I. [1 ]
Iacobucci, I. [1 ]
Cozzolino, F. [1 ]
Morasso, S. [2 ]
Storici, P. [2 ]
Iaconis, D. [3 ]
Talarico, C. [3 ]
Manelfi, C. [4 ]
Beccari, A. [3 ]
Monti, M. [1 ]
机构：
[1] Univ Naples Federico II, Naples, Italy
[2] Elettra Sincrotrone Trieste, Trieste, Italy
[3] Dompe Farmaceut SpA, Naples, Italy
[4] Dompe Farmaceut SpA, Laquila, Italy
来源：
FEBS OPEN BIO | 2024年 / 14卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P-34-024
引用
收藏
页码：422 / 422
页数：1
相关论文
共 50 条
  • [21] Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease
    Graf, Dominic
    Farn, Nikolas
    Klopf, Jonas
    Hojjati, Mahniya
    Schatzschneider, Ulrich
    METALLOMICS, 2023, 15 (05)
  • [22] Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
    Ferreira, Juliana C.
    Fadl, Samar
    Rabeh, Wael M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (06)
  • [23] Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity
    Garland, Gavin D.
    Harvey, Robert F.
    Mulroney, Thomas E.
    Monti, Mie
    Fuller, Stewart
    Haigh, Richard
    Gerber, Pehuen Pereyra
    Barer, Michael R.
    Matheson, Nicholas J.
    Willis, Anne E.
    BIOCHEMICAL JOURNAL, 2022, 479 (08) : 901 - 920
  • [24] Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants
    Jukic, Marko
    Skrlj, Blaz
    Tomsic, Gasper
    Plesko, Sebastian
    Podlipnik, Crtomir
    Bren, Urban
    MOLECULES, 2021, 26 (10):
  • [25] SARS-CoV-2 3CLpro (main protease) regulates caspase activation of gasdermin-D/E pores leading to secretion and extracellular activity of 3CLpro
    Grin, Peter M.
    Baid, Kaushal
    de Jesus, Hugo C. R.
    Kozarac, Nedim
    Bell, Peter A.
    Jiang, Steven Z.
    Kappelhoff, Reinhild
    Butler, Georgina S.
    Leborgne, Nathan G. F.
    Pan, Christina
    Pablos, Isabel
    Machado, Yoan
    Vederas, John C.
    Kim, Hugh
    Benarafa, Charaf
    Banerjee, Arinjay
    Overall, Christopher M.
    CELL REPORTS, 2024, 43 (12):
  • [26] Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
    Zhu, Jiajie
    Zhang, Haiyan
    Lin, Qinghong
    Lyu, Jingting
    Lu, Lu
    Chen, Hanxi
    Zhang, Xuning
    Zhang, Yanjun
    Chen, Keda
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1067 - 1082
  • [27] Insilico generation of novel ligands for the inhibition of SARS-CoV-2 main protease (3CLpro) using deep learning
    Prabhakaran, Prejwal
    Hebbani, Ananda Vardhan
    Menon, Soumya V.
    Paital, Biswaranjan
    Murmu, Sneha
    Kumar, Sunil
    Singh, Mahender Kumar
    Sahoo, Dipak Kumar
    Desai, Padma Priya Dharmavaram
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [28] Chlorogenic acid may be a potent inhibitor of dimeric SARS-CoV-2 main protease 3CLpro: an in silico study
    Patil, Rajkumar Sanjay
    Khatib, Nayeem A.
    Patil, Vishal Shivalingappa
    Suryawanshi, Shailendra Sanjay
    TRADITIONAL MEDICINE RESEARCH, 2021, 6 (02):
  • [29] Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020
    Chen, Roufen
    Gao, Yali
    Liu, Han
    Li, He
    Chen, Wenfa
    Ma, Junjie
    RSC MEDICINAL CHEMISTRY, 2023, 14 (01): : 9 - 21
  • [30] Sub-Micromolar Inhibition of SARS-CoV-2 3CLpro by Natural Compounds
    Rizzuti, Bruno
    Ceballos-Laita, Laura
    Ortega-Alarcon, David
    Jimenez-Alesanco, Ana
    Vega, Sonia
    Grande, Fedora
    Conforti, Filomena
    Abian, Olga
    Velazquez-Campoy, Adrian
    PHARMACEUTICALS, 2021, 14 (09)
12345